1. Academic Validation
  2. Enhanced CXCL12/CXCR4 signaling increases tumor progression in radiation‑resistant pancreatic cancer

Enhanced CXCL12/CXCR4 signaling increases tumor progression in radiation‑resistant pancreatic cancer

  • Oncol Rep. 2022 Apr;47(4):68. doi: 10.3892/or.2022.8279.
Tomokatsu Kato 1 Yoichi Matsuo 1 Goro Ueda 1 Hiromichi Murase 1 Yoshinaga Aoyama 1 Kan Omi 1 Yuichi Hayashi 1 Hiroyuki Imafuji 1 Kenta Saito 1 Mamoru Morimoto 1 Ryo Ogawa 1 Hiroki Takahashi 1 Shuji Takiguchi 1
Affiliations

Affiliation

  • 1 Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467‑8601, Japan.
Abstract

Pancreatic Cancer (PaCa) exhibits one of the poorest prognoses among all gastrointestinal cancers due to the rapid development of treatment resistance, which renders chemotherapy and radiotherapy no longer effective. However, the mechanisms through which PaCa becomes resistant to radiotherapy are unknown. Here, we established radiation‑resistant PaCa cell lines to investigate the factors involved in radiation resistance. The role of the C‑X‑C motif chemokine ligand 12 (CXCL12)/C‑X‑C Chemokine Receptor type 4 (CXCR4) axis in radiation resistance in PaCa and the effects of a CXCR4 Antagonist on radiation‑resistant PaCa cell lines were investigated. As confirmed by immunofluorescence staining, reverse transcription quantitative polymerase chain reaction, and western blotting, the expression of CXCR4 was higher in radiation‑resistant PaCa cell lines than that noted in normal PaCa cell lines. The invasion ability of radiation‑resistant PaCa cell lines was greater than that of normal cell lines and was enhanced by CXCL12 treatment and coculture with fibroblasts; this enhanced invasion ability was suppressed by the CXCR4 Antagonist AMD070. Irradiation after treatment with the CXCR4 Antagonist suppressed the colonization of radiation‑resistant PaCa cell lines. In conclusion, the CXCL12/CXCR4 axis may be involved in the radiation resistance of PaCa. These findings may facilitate the development of novel treatments for PaCa.

Keywords

CXCL12; CXCR4; CXCR4 antagonist; pancreatic cancer; radiation‑resistant.

Figures
Products